Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors

manilatimes.net · 2026-08-12

CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C. Reed, M.D., Ph.D., to its Board of Directors.

TickrTrends take: Madrigal's appointment of John C. Reed, M.D., Ph.D., to its board adds scientific and medical expertise to the company's governance during a period when TickrTrends awaits sufficient data to complete a full valuation assessment. In the Healthcare sector, board composition and the caliber of medical leadership can influence investor confidence in a company's strategic direction and pipeline oversight. Valuation-focused readers should monitor whether this appointment correlates with any announcements regarding clinical progress, regulatory milestones, or strategic initiatives that could provide the data points needed to move from a valuation-pending status to a completed assessment.

Read the full story at manilatimes.net →